- Trial phase
- Approved
- Time to market
- Already marketed (FDA approved March 2016).
- Why 3/10
- Odefsey is an already-approved, marketed drug with no pending regulatory decision or pivotal readout in the next 12 months. It is a small part of Gilead's large, diversified pipeline and HIV portfolio (led by Biktarvy). Per the rubric, an approved drug with no imminent binary catalyst scores 3-5, and Odefsey's minor contribution to Gilead's overall value places it at the low end of that range.
Odefsey has no upcoming binary catalyst; the next material event for the drug would be generic entry risk around 2033. Gilead's stock is driven by the broader HIV franchise (led by Biktarvy), oncology drug Trodelvy, and pipeline developments like the islatravir/lenacapavir once-weekly HIV regimen partnered with Merck. Watch Gilead's quarterly HIV sales breakdown and any Paragraph IV patent settlement updates for Odefsey.
Price Chart
Executive Summary
Odefsey is a once-daily single-tablet HIV-1 regimen combining emtricitabine, rilpivirine, and tenofovir alafenamide, approved by the FDA in March 2016 and marketed by Gilead Sciences (GILD). It is a mature, commercially established product within Gilead's large HIV portfolio, which is dominated by the newer and much larger-selling Biktarvy ($4.1B in Q3 2026). Odefsey faces no imminent regulatory catalysts, and its patent-protected exclusivity is estimated to run until early 2033. For a Gilead investor, Odefsey is a stable but minor contributor to the company's overall HIV franchise revenue.
How It Works
Odefsey combines three antiviral drugs into one daily pill. Two of them (emtricitabine and tenofovir alafenamide) are NRTIs, which block HIV from copying its genetic material. The third (rilpivirine) is an NNRTI, which disables a protein HIV needs to replicate. Together they suppress the virus to undetectable levels in people with HIV.
Trial Status
Odefsey was approved by the FDA on March 1, 2016, based on Phase 3 clinical data demonstrating efficacy and safety as a complete regimen for HIV-1 treatment in treatment-naive adults and adolescents. The drug is widely marketed and prescribed, with a boxed warning about hepatitis B exacerbation upon discontinuation. The FDA label was most recently updated in December 2025.
The Two-Sided Case
Upcoming Catalysts
- No upcoming PDUFA or pivotal readout for Odefsey (already approved and marketed).
- Patent expiry / generic entry risk around February 2033, subject to any Paragraph IV settlement.
- Any Paragraph IV patent challenge settlement could bring earlier generic competition.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
GILEAD SCIENCES, INC. 8-K GILD ·Originating report